The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting

Journal of Alzheimer's Disease

Volumn 60, Issue 2, 2017, Pages 561-576

  Niemantsverdriet, Ellis ^a   Ottoy, Julie ^b   Somers, Charisse ^a   De Roeck, Ellen ^a,c   Struyfs, Hanne ^a   Soetewey, Femke ^a   Verhaeghe, Jeroen ^b   Van Den Bossche, Tobi ^a,d,e   Van Mossevelde, Sara ^a,d,e   Goeman, Johan ^e   De Deyn, Peter Paul ^a,e   Mariën, Peter ^c,e   Versijpt, Jan ^f   Sleegers, Kristel ^a,d   Van Broeckhoven, Christine ^a,d   Wyffels, Leonie ^b,g   Albert, Adrien ^g   Ceyssens, Sarah ^g   Stroobants, Sigrid ^b,g   Staelens, Steven ^b   Bjerke, Maria ^a   Engelborghs, Sebastiaan ^a,e   more..

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Molecular Imaging Center Antwerp   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e Memory Clinic   (Belgium)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

amyloid; amyloid imaging; A 1 42 A 1 40 ratio; biomarkers; cerebrospinal fluid; magnetic resonance imaging; 18F Florbetapir ( 18F AV45)

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AV45 F 18; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; TAURINE TRANSPORTER; TAUROCYAMINE KINASE; TRACER; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; PEPTIDE FRAGMENT; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; APATHY EVALUATION SCALE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID AMYLOID BETA PROTEIN[1-40] RATIO; CEREBROSPINAL FLUID AMYLOID BETA PROTEIN[1-42] RATIO; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION RATIO; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DEPRESSION ASSESSMENT; FEMALE; GRAY MATTER; HUMAN; LONGITUDINAL STUDY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET-CT SCANNER; PHARMACOKINETIC PARAMETERS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; VOLUME OF DISTRIBUTION; WHITE MATTER; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; THREE DIMENSIONAL IMAGING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; COGNITIVE DYSFUNCTION; ETHYLENE GLYCOLS; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; TAU PROTEINS;

EID: 85029618099     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-170327     Document Type: Article

References (63)

1. Haass C, Selkoe DJ (1993) Cellular processing of betaamyloid precursor protein and the genesis of amyloid beta-peptide. Cell 75, 1039-1042.
2. Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K (2011) A novel pathway for amyloid precursor protein processing. Neurobiol Aging 32, 1090-1098.
3. Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 12, 207-216.
4. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging B, Lifestyle Research G (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12, 357-367.
5. Sanchez L, Madurga S, Pukala T, Vilaseca M, Lopez-Iglesias C, Robinson CV, Giralt E, Carulla N (2011) Abeta40 and Abeta42 amyloid fibrils exhibit distinct molecular recycling properties. J Am Chem Soc 133, 6505-6508.
6. Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Associationworkgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 257-262.
7. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
8. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack Jr CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
9. Alberts MJ, Latchaw RE, Jagoda A, Wechsler LR, Crocco T, George MG, Connolly ES, Mancini B, Prudhomme S, Gress D, Jensen ME, Bass R, Ruff R, Foell K, Armonda RA, Emr M, Warren M, Baranski J, Walker MD, Brain Attack C (2011) Revised and updated recommendations for the establishment of primary stroke centers: A summary statement from the brain attack coalition. Stroke 42, 2651-2665.
10. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol 13, 614-629.
11. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519.
12. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM, Group AAS (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305, 275-283.
13. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25, 1528-1547.
14. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative (2013) The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 9, e111-194.
15. Svedberg MM, Hall H, Hellstrom-Lindahl E, Estrada S, Guan Z, Nordberg A, Langstrom B (2009) [(11)C]PIBamyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int 54, 347-357.
16. Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW, Alzheimer's Disease Neuroimaging Initiative (2015) Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease. Brain 138, 772-783.
17. Zwan M, van Harten A, Ossenkoppele R, Bouwman F, Teunissen C, Adriaanse S, Lammertsma A, Scheltens P, van Berckel B, van der Flier W (2014) Concordance between cerebrospinal fluid biomarkers and [11C]PIBPETin amemory clinic cohort. J Alzheimers Dis 41, 801-807.
18. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hagerstrom D, Wollmer P, Minthon L, Hansson O (2014) Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: A cross-validation study against amyloid positron emission tomography. JAMA Neurol 71, 1282-1289.
19. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA, Alzheimer's Disease Neuroimaging Initiative (2009) Relationships between biomarkers in aging and dementia. Neurology 73, 1193-1199.
20. Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, Shaw LM, Jagust WJ, Alzheimer's Disease Neuroimaging Initiative (2013) Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol 74, 826-836.
21. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29, 1456-1465.
22. Degerman Gunnarsson M, Lindau M, Wall A, Blennow K, Darreh-Shori T, Basu S, Nordberg A, Larsson A, Lannfelt L, Basun H (2010) Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study. Dement Geriatr Cogn Disord 29, 204-212.
23. Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A (2015) Concordance and diagnostic accuracy of [11C]PIB PET and cerebrospinal fluid biomarkers in a sample of patients with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 45, 1077-1088.
24. Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleo A, Herukka SK, Soininen H, Law I, Bahl JM, Carter SF, Fortea J, Blesa R, Teunissen CE, Bouwman FH, van Berckel BN, Visser PJ (2016) Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. Neurology 86, 50-58.
25. Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, vanWesten D, Stomrud E, Minthon L, Blennow K, Swedish BioFINDER study group, Hansson O (2016) CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: Better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 3, 154-165.
26. Palmqvist S, Mattsson N, Hansson O, Alzheimer's Disease Neuroimaging Initiative (2016) Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain 139, 1226-1236.
27. Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, Nagren K, Rokka J, Haaparanta M, Kalimo H, Rinne JO (2008) PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 131, 1845-1853.
28. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack Jr CR, Alzheimer's Disease Neuroimaging Initiative (2011) Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. Alzheimers Dement 7, 133-141.
29. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN (2009) Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 50, 1464-1470.
30. Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonca A, Otto M, Lleo A, Castelo-Branco M, Santana I, Johansson J, Anderl-Straub S, von Arnim CA, Beer A, Blesa R, Fortea J, Herukka SK, Portelius E, Pannee J, Zetterberg H, Blennow K, Nordberg A (2016) Pittsburgh compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European memory clinic study. Brain 139, 2540-2553.
31. Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, Kornhuber J, Morris JC, Fagan AM (2017) Cerebrospinal fluid Abeta42/40 corresponds better than Abeta42 to amyloid PET in Alzheimer's disease. J Alzheimers Dis 55, 813-822.
32. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65, 176-183.
33. Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A (2010) High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 7, 56-66.
34. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J (2015) Amyloid-beta 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: Validation of two novel assays. J Alzheimers Dis 43, 183-191.
35. Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H, Frolich L, Schroder J, Peters O, Jessen F, Luckhaus C, Perneczky R, Jahn H, Fiszer M, Maler JM, Zimmermann R, Bruckmoser R, Kornhuber J, Lewczuk P (2007) Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low-and high-CSF A beta 40 load. J Neurochem 101, 1053-1059.
36. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K (2007) Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23, 316-320.
37. Ottoy J, Verhaeghe J, Niemantsverdriet E, Wyffels L, Somers C, De Roeck E, Struyfs H, Soetewey F, Deleye S, Van den Bossche T, Van Mossevelde S, Ceyssens S, Versijpt J, Stroobants S, Engelborghs S, Staelens S (2017) Validation of the semi-quantitative static SUVR method for [18F]-AV45 PET by pharmacokinetic modeling with an arterial input function. J Nucl Med. doi: 10.2967/jnumed.116.184481
38. Koeppe RA (2014) The Centiloid method for quantifying Amyloid PET studies: Great illuminator or master or illusion. In Human Amyloid Imaging, Miami, Florida.
39. van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, Scheltens P, Lammertsma AA, Boellaard R (2013) Longitudinal amyloid imaging using 11C-PiB: Methodologic considerations. J Nucl Med 54, 1570-1576.
40. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI (1990) Clarifying confusion: The confusion assessment method. A new method for detection of delirium. Ann Intern Med 113, 941-948.
41. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA:Abrief screening tool for mild cognitive impairment. J Am Geriatr Soc 53, 695-699.
42. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149, 698-709.
43. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
44. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C (2002) Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 73, 126-133.
45. Nelson HE (1982) National Adult Reading Test (NART): For the Assessment of Premorbid Intelligence in Patients with Dementia: Test Manual. NFER-Nelson, Windsor, UK.
46. Randolph C, Tierney MC, Mohr E, Chase TN (1998) The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary clinical validity. J Clin Exp Neuropsychol 20, 310-319.
47. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1982) Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 17, 37-49.
48. Marin RS, Biedrzycki RC, Firinciogullari S (1991) Reliability and validity of the apathy evaluation scale. Psychiatry Res 38, 143-162.
49. Morris JC (1997) Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 9(Suppl 1), 173-176; discussion 177-178.
50. Cummings JL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 48, S10-S16.
51. Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck N, De Roeck E, De Vil B, Cras P, Martin JJ, De Deyn PP, Bjerke M, Engelborghs S (2016) A decade of cerebrospinal fluid biomarkers for Alzheimer's disease in Belgium. J Alzheimers Dis 54, 383-395.
52. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29, 1143-1159.
53. Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Marien P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S (2014) Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: A longitudinal study. J Alzheimers Dis 42, 1239-1250.
54. Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S (2013) Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis 36, 759-767.
55. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J (1992) Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55, 967-972.
56. Rorden C, Bonilha L, Fridriksson J, Bender B, Karnath HO (2012) Age-specific CT and MRI templates for spatial normalization. Neuroimage 61, 957-965.
57. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of betaamyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106.
58. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Kaeser SA, Lachno DR, Lleo A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman RA, Rosenmann H, Sancesario G, Schroder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, Alzheimer's Association QC Program Work Group (2013) CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 9, 251-261.
59. Vos SJ, Visser PJ, Verhey F, Aalten P, Knol D, Ramakers I, Scheltens P, Rikkert MG, Verbeek MM, Teunissen CE (2014) Variability of CSF Alzheimer's disease biomarkers: Implications for clinical practice. PLoS One 9, e100784.
60. Brendel M, Hogenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, Rominger A, Alzheimer's Disease Neuroimaging Initiative (2015) Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage 108, 450-459.
61. Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, Protas H, Luo JL, Bauer R, Reschke C, Bandy D, Koeppe RA, Fleisher AS, Caselli RJ, Landau S, Jagust WJ, Weiner MW, Reiman EM, Alzheimer's Disease Neuroimaging Initiative (2015) Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med 56, 560-566.
62. Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, Reiman EM, Jagust WJ (2015) Measurement of longitudinal beta-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med 56, 567-574.
63. Shokouhi S, McKay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, Riddle WR, Claassen DO, Rogers BP, Alzheimer's Disease Neuroimaging Initiative (2016) Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment. Alzheimers Res Ther 8, 2.